Paper42680902
New thinking for the next generation of antimalarials.
Asiki H and 4 others. EMBO Mol Med, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. New thinking for the next generation of antimalarials. Papers, record 42680902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42680902
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimalarials | Major topic |
| Drug Discovery | Major topic |
| Malaria | Major topic |
| Plasmodium | Major topic |
| Humans | |
| Animals | |
| Drug Repositioning | |
| Drug Resistance |
Source PubMed
References149
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39402081 | Computational approach for decoding malaria drug targets from single-cell transcriptomics and finding potential drug molecule. | Sci Rep | 2024 | https://conductscience.org/library/papers/39402081 | PubMed |
| 2 | 24950358 | Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. | Vaccine | 2014 | https://conductscience.org/library/papers/24950358 | PubMed |
| 3 | 42287204 | The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation. | ACS Chem Biol | 2026 | https://conductscience.org/library/papers/42287204 | PubMed |
| 4 | 22390538 | 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. | J Med Chem | 2012 | https://conductscience.org/library/papers/22390538 | PubMed |
| 5 | 37652975 | Antimalarial drug discovery: progress and approaches. | Nat Rev Drug Discov | 2023 | https://conductscience.org/library/papers/37652975 | PubMed |
| 6 | 26030447 | Plasmodium falciparum genetic crosses in a humanized mouse model. | Nat Methods | 2015 | https://conductscience.org/library/papers/26030447 | PubMed |
| 7 | 34553687 | Common host variation drives malaria parasite fitness in healthy human red cells. | Elife | 2021 | https://conductscience.org/library/papers/34553687 | PubMed |
| 8 | 36266336 | CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery. | Nat Microbiol | 2022 | https://conductscience.org/library/papers/36266336 | PubMed |
| 9 | 28688800 | Protein Degradation Systems as Antimalarial Therapeutic Targets. | Trends Parasitol | 2017 | https://conductscience.org/library/papers/28688800 | PubMed |
| 10 | 33590753 | Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. | ACS Infect Dis | 2021 | https://conductscience.org/library/papers/33590753 | PubMed |
| 11 | 39441986 | Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment. | J Med Chem | 2024 | https://conductscience.org/library/papers/39441986 | PubMed |
| 12 | 27247245 | Phenotypic Screens in Antimalarial Drug Discovery. | Trends Parasitol | 2016 | https://conductscience.org/library/papers/27247245 | PubMed |
| 13 | 36856421 | Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc. | Antimicrob Agents Chemother | 2023 | https://conductscience.org/library/papers/36856421 | PubMed |
| 14 | 34523908 | Prioritization of Molecular Targets for Antimalarial Drug Discovery. | ACS Infect Dis | 2021 | https://conductscience.org/library/papers/34523908 | PubMed |
| 15 | 31170268 | Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. | PLoS Pathog | 2019 | https://conductscience.org/library/papers/31170268 | PubMed |
| 16 | 21957167 | Disclosure of clinical trial results when product development is abandoned. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21957167 | PubMed |
| 17 | 35439421 | The Ascension of Targeted Covalent Inhibitors. | J Med Chem | 2022 | https://conductscience.org/library/papers/35439421 | PubMed |
| 18 | 23511784 | Phenotypic vs. target-based drug discovery for first-in-class medicines. | Clin Pharmacol Ther | 2013 | https://conductscience.org/library/papers/23511784 | PubMed |
| 19 | 31978322 | The Antimalarial Natural Product Salinipostin A Identifies Essential α/β Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites. | Cell Chem Biol | 2020 | https://conductscience.org/library/papers/31978322 | PubMed |
| 20 | 39607932 | Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance. | Science | 2024 | https://conductscience.org/library/papers/39607932 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42680902
GET https://conductscience.org/api/papers/v1/42680902/references?page=2